Company news: Eli Lilly

Share this article:
Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes,  met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin. The most frequently reported adverse events were gastrointestinal-related and consistent with prior studies, said the company. A number of additional studies are ongoing as part of the AWARD battery.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions